Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
Identifieur interne : 001605 ( PubMed/Corpus ); précédent : 001604; suivant : 001606Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
Auteurs : Yu-Xuan Hou ; Cheng Peng ; Zheng-Gang Han ; Peng Zhou ; Ji-Guo Chen ; Zheng-Li ShiSource :
- Virologica Sinica [ 1995-820X ] ; 2010.
English descriptors
- KwdEn :
- Adenoviridae (genetics), Animals, Antibodies, Neutralizing, Antibodies, Viral (blood), Chiroptera (virology), Cross Reactions, Female, Gene Expression, Genetic Vectors, HIV (genetics), Humans, Interferon-gamma (metabolism), Interleukin-6 (metabolism), Leukocytes, Mononuclear (immunology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Neutralization Tests, Recombinant Proteins (genetics), Recombinant Proteins (immunology), SARS Virus (genetics), SARS Virus (immunology), SARS Virus (isolation & purification), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Membrane Glycoproteins, Recombinant Proteins, Viral Envelope Proteins.
- chemical , immunology : Membrane Glycoproteins, Recombinant Proteins, Viral Envelope Proteins, Viral Vaccines.
- chemical , metabolism : Interferon-gamma, Interleukin-6.
- chemical : Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus.
- genetics : Adenoviridae, HIV, SARS Virus.
- immunology : Leukocytes, Mononuclear, SARS Virus.
- isolation & purification : SARS Virus.
- virology : Chiroptera.
- Animals, Cross Reactions, Female, Gene Expression, Genetic Vectors, Humans, Mice, Mice, Inbred BALB C, Neutralization Tests.
Abstract
A group of SARS-like coronaviruses (SL-CoV) have been identified in horseshoe bats. Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity, SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64% amino acid identity, suggesting there are fundamental differences between these two groups of coronaviruses. To gain insight into the basis of this difference, we established a recombinant adenovirus system expressing the S protein from SL-CoV (rAd-Rp3-S) to investigate its immune characterization. Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein. Moreover, a strong cellular immune response demonstrated by elevated IFN-γ and IL-6 levels was also observed in these mice. However, the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein, and did not neutralize HIV pseudotyped with SARS-CoV S protein. These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV, which may cause the immunological differences between human SARS-CoV and bat SL-CoV. Furthermore, the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection.
DOI: 10.1007/s12250-010-3096-2
PubMed: 20960282
Links to Exploration step
pubmed:20960282Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.</title><author><name sortKey="Hou, Yu Xuan" sort="Hou, Yu Xuan" uniqKey="Hou Y" first="Yu-Xuan" last="Hou">Yu-Xuan Hou</name><affiliation><nlm:affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.</nlm:affiliation></affiliation></author><author><name sortKey="Peng, Cheng" sort="Peng, Cheng" uniqKey="Peng C" first="Cheng" last="Peng">Cheng Peng</name></author><author><name sortKey="Han, Zheng Gang" sort="Han, Zheng Gang" uniqKey="Han Z" first="Zheng-Gang" last="Han">Zheng-Gang Han</name></author><author><name sortKey="Zhou, Peng" sort="Zhou, Peng" uniqKey="Zhou P" first="Peng" last="Zhou">Peng Zhou</name></author><author><name sortKey="Chen, Ji Guo" sort="Chen, Ji Guo" uniqKey="Chen J" first="Ji-Guo" last="Chen">Ji-Guo Chen</name></author><author><name sortKey="Shi, Zheng Li" sort="Shi, Zheng Li" uniqKey="Shi Z" first="Zheng-Li" last="Shi">Zheng-Li Shi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20960282</idno><idno type="pmid">20960282</idno><idno type="doi">10.1007/s12250-010-3096-2</idno><idno type="wicri:Area/PubMed/Corpus">001605</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001605</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.</title><author><name sortKey="Hou, Yu Xuan" sort="Hou, Yu Xuan" uniqKey="Hou Y" first="Yu-Xuan" last="Hou">Yu-Xuan Hou</name><affiliation><nlm:affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.</nlm:affiliation></affiliation></author><author><name sortKey="Peng, Cheng" sort="Peng, Cheng" uniqKey="Peng C" first="Cheng" last="Peng">Cheng Peng</name></author><author><name sortKey="Han, Zheng Gang" sort="Han, Zheng Gang" uniqKey="Han Z" first="Zheng-Gang" last="Han">Zheng-Gang Han</name></author><author><name sortKey="Zhou, Peng" sort="Zhou, Peng" uniqKey="Zhou P" first="Peng" last="Zhou">Peng Zhou</name></author><author><name sortKey="Chen, Ji Guo" sort="Chen, Ji Guo" uniqKey="Chen J" first="Ji-Guo" last="Chen">Ji-Guo Chen</name></author><author><name sortKey="Shi, Zheng Li" sort="Shi, Zheng Li" uniqKey="Shi Z" first="Zheng-Li" last="Shi">Zheng-Li Shi</name></author></analytic><series><title level="j">Virologica Sinica</title><idno type="eISSN">1995-820X</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae (genetics)</term><term>Animals</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral (blood)</term><term>Chiroptera (virology)</term><term>Cross Reactions</term><term>Female</term><term>Gene Expression</term><term>Genetic Vectors</term><term>HIV (genetics)</term><term>Humans</term><term>Interferon-gamma (metabolism)</term><term>Interleukin-6 (metabolism)</term><term>Leukocytes, Mononuclear (immunology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Recombinant Proteins (genetics)</term><term>Recombinant Proteins (immunology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (isolation & purification)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interferon-gamma</term><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviridae</term><term>HIV</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Leukocytes, Mononuclear</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Chiroptera</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cross Reactions</term><term>Female</term><term>Gene Expression</term><term>Genetic Vectors</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A group of SARS-like coronaviruses (SL-CoV) have been identified in horseshoe bats. Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity, SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64% amino acid identity, suggesting there are fundamental differences between these two groups of coronaviruses. To gain insight into the basis of this difference, we established a recombinant adenovirus system expressing the S protein from SL-CoV (rAd-Rp3-S) to investigate its immune characterization. Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein. Moreover, a strong cellular immune response demonstrated by elevated IFN-γ and IL-6 levels was also observed in these mice. However, the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein, and did not neutralize HIV pseudotyped with SARS-CoV S protein. These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV, which may cause the immunological differences between human SARS-CoV and bat SL-CoV. Furthermore, the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20960282</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.</ArticleTitle><Pagination><MedlinePgn>36-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12250-010-3096-2</ELocationID><Abstract><AbstractText>A group of SARS-like coronaviruses (SL-CoV) have been identified in horseshoe bats. Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity, SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64% amino acid identity, suggesting there are fundamental differences between these two groups of coronaviruses. To gain insight into the basis of this difference, we established a recombinant adenovirus system expressing the S protein from SL-CoV (rAd-Rp3-S) to investigate its immune characterization. Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein. Moreover, a strong cellular immune response demonstrated by elevated IFN-γ and IL-6 levels was also observed in these mice. However, the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein, and did not neutralize HIV pseudotyped with SARS-CoV S protein. These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV, which may cause the immunological differences between human SARS-CoV and bat SL-CoV. Furthermore, the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yu-xuan</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Cheng</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Zheng-gang</ForeName><Initials>ZG</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ji-guo</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Zheng-li</ForeName><Initials>ZL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002685" MajorTopicYN="N">Chiroptera</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20960282</ArticleId><ArticleId IdType="doi">10.1007/s12250-010-3096-2</ArticleId><ArticleId IdType="pmc">PMC7090579</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2008 Jul 16;3(7):e2685</Citation><ArticleIdList><ArticleId IdType="pubmed">18628832</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(4):2001-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15681402</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Aug;80(15):7481-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16840328</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2004 Sep 1;120(1):87-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15234813</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Jun 29;24(26):5498-508</Citation><ArticleIdList><ArticleId IdType="pubmed">16725238</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2006 May 26;344(1):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16615996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2005 Jan;123(1):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15582697</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Feb;82(4):1899-907</Citation><ArticleIdList><ArticleId IdType="pubmed">18077725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jun;80(12):5757-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16731915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1998 Jun 15;58(12):2489-99</Citation><ArticleIdList><ArticleId IdType="pubmed">9635566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2005 Sep;112(1-2):24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16022898</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1992 Jul;189(1):88-102</Citation><ArticleIdList><ArticleId IdType="pubmed">1318616</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2007 Sep;128(1-2):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17532082</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Jan 23;313(4):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">14706633</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1990 Aug;177(2):646-56</Citation><ArticleIdList><ArticleId IdType="pubmed">2164728</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Jul 20;351(1):180-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16647731</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Sep;79(18):11638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16140741</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15356154</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001605 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001605 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20960282
|texte= Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20960282" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |